{"id":676732,"date":"2023-11-15T16:02:02","date_gmt":"2023-11-15T16:02:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=676732"},"modified":"2023-11-15T16:02:02","modified_gmt":"2023-11-15T16:02:02","slug":"atrial-fibrillation-market-to-register-sustainable-growth-during-the-forecast-period-20232032-delveinsight-vivasc-arca-biopharma-hyloris-anthos-therapeutics-milestone-pharma-hanmi-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/atrial-fibrillation-market-to-register-sustainable-growth-during-the-forecast-period-20232032-delveinsight-vivasc-arca-biopharma-hyloris-anthos-therapeutics-milestone-pharma-hanmi-pharma_676732.html","title":{"rendered":"Atrial Fibrillation Market to Register Sustainable Growth During the Forecast Period (2023-2032) – DelveInsight | Vivasc, ARCA Biopharma, Hyloris, Anthos Therapeutics, Milestone Pharma, Hanmi Pharma"},"content":{"rendered":"
\n
\"Atrial<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Atrial Fibrillation Market is anticipated to evolve immensely in the coming years owing to the expected approval of emerging therapies and the increasing prevalence of atrial fibrillation in the 7MM.<\/div>\n

DelveInsight’s “Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Atrial Fibrillation market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Atrial Fibrillation drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Atrial Fibrillation treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Atrial Fibrillation: An Overview<\/strong><\/p>\n

Atrial fibrillation, often called AFib or AF, is the leading cardiac cause of stroke and is the most common type of cardiac arrhythmia. It is characterized by rapid and irregular beating of the atrial chambers of the heart, due to abnormal electrical activity, because of which the blood doesn’t flow as well as it should from the atria to the two ventricles. This lack of coordination between the upper and lower chambers causes irregular heartbeat.<\/p>\n

Either the disease may be episodic, or a permanent condition and can begin as an atrial flutter that transforms into AF. Any condition that leads to inflammation, stress, damage, or ischemia affecting the anatomy of the heart can result in the development of atrial fibrillation. In some cases, the cause is iatrogenic.<\/p>\n

The three patterns of atrial fibrillation include paroxysmal, which occurs spontaneously and generally resolves by itself or with treatment within seven days, and persistent, which is for more than seven days and needs either pharmacological or electrical cardioversion. It might lead to electrical remodeling in the cardiac myocytes causing dilated cardiomyopathy and is usually a result of recurrent episodes of paroxysmal AF. The third is long-standing persistent AF that has been present for more than 12 months, either due to the failure of initiation of pharmacological intervention or failure of cardioversion. Permanent AF is where a decision has been made to abort all therapies because the rhythm is unresponsive.<\/p>\n

Atrial Fibrillation Market Key Facts<\/strong><\/p>\n